RePORT International Resources

Access the SEATRAC Advanced TB Training recordings for 2023 and 2024 through this link.This virtual program offered by the University of Washington's SEATRAC, which provides advanced, multidisciplinary training in TB research. It covers key domains such as immunology and vaccines, pathogenesis and treatment, diagnostics, transmission, disease modeling, implementation science, and advocacy, geared toward both emerging and experienced investigators engaging in TB research.

This Notice of Funding Opportunity (NOFO) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The NOFO aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed. Please refer to the website for detail announcement and key dates.

The Southeastern National Tuberculosis Center (SNTC) archived webinar library features recorded sessions covering diagnostics, treatment, prevention, and comorbidities, aimed at expanding individuals' knowledge and skills in tuberculosis care.

The SAMRC’s vision is to build a healthy nation through research and innovation. For this vision to be realised, health researchers (locally and internationally) need funding to access the necessary resources and facilities. While the SAMRC funds many internal and external research projects itself, as well as in collaboration with partnering institutions, it also connects innovative researchers with like-minded organisations across the world that provide funding opportunities.

The Southeastern National Tuberculosis Center (SNTC) offers education, training, research support, and program development resources for healthcare professionals and public health providers. Please explore the website for more details.

Video in multiple languages for collecting sputum sample

This questionnaire was designed for symptom measurement for persons with COPD and asthma. However, it is commonly used for persons with pulmonary TB in both clincal and reseatch settings.

Watch webinars, event recordings, and advocacy videos from the Stop TB Partnership.

A session from the 78th World Health Assembly focused on new financing models and emerging technologies in TB. Speakers emphasized sustainable investment and digital health tools to improve prevention, diagnosis, and treatment.

This session called for increased domestic TB funding in Africa, private sector engagement, and innovation in service delivery, governance, and regulation—underscoring community-driven and politically aligned strategies.

Several training packages.

This three-part webinar series by the Stop TB Partnership and FIND provides an in-depth overview of targeted next-generation sequencing (tNGS) technology for detecting drug-resistant tuberculosis. The series covers fundamental principles of tNGS, its advantages over traditional diagnostic methods, and practical guidance on implementing tNGS in high-burden and resource-limited settings. Featuring expert insights and case studies, the webinars highlight early program experiences and discuss how tNGS supports WHO-endorsed strategies to improve rapid and comprehensive detection of TB drug resistance worldwide.

This website features TAG’s latest updates in the fight to end HIV/AIDS, Hepatitis C, and Tuberculosis. It includes the Pipeline Report on innovations in diagnosing, preventing, treating, and curing HIV, HCV, and TB; information on TB research funding; recorded webinars; advocacy letters and comments submitted or endorsed by TAG; and official press releases and statements.

Please refer to the link for the TAG's latest edition of TB Treatment Pipeline Report. The report provides the latest information on 22 new or repurposed drugs in clinical development for TB and summarizes ongoing, planned, and recently completed trials. Included in this year's report are: Results from the phase 3 endTB-Q trial and two phase 2b/c trials of quabodepistat-containing regimens completed or discontinued in 2024; First-of-their-kind trials focused on asymptomatic TB and bedaquiline-resistant TB; The first long-acting formulation of a TB drug to enter clinical development; and The first phase 3 trial of a new drug from a new class since bedaquiline and delamanid.

The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB. The Activist Guide reviews the evidence-base behind these regimens, important considerations for key populations affected by TB, the access landscape, and more. The publication is intended to equip advocates with information they need to formulate arguments and push for universal implementation of the best available treatments.

TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:

The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs. Despite this progress, 2.7 million individuals with TB still remain undiagnosed and undetected. On July 17th, 2025, TAG hosted a community webinar on tests for TB and drug resistance. The webinar breaks down the latest WHO guidelines and explores the most effective tools for diagnosing TB and drug resistance. The webinar also launched TAG’s updated resource, An Activist’s Guide to Diagnostic Tools for Tuberculosis, and provides a deep dive into two sections of the Guide: (1) the array of WHO-recommended diagnostic tools and how they should be optimally used in country programs; and (2) key access considerations and actions activists can take to ensure that all people at risk of TB receive quality TB diagnostic testing.

The Tuberculosis Data, Impact Assessment and Communications Hub (TB DIAH) supports decision-makers by generating, analyzing, and utilizing quality data to inform and scale up effective TB services. This website provides resources on TB M&E and surveillance processes.

Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) released the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB. By documenting the representativeness of TB studies, community advisors and researchers can work together to ensure that all people in need of safe and effective options for treating and preventing TB can benefit from research.